Zydus Cadila on Friday announced that it has received restricted emergency use approval from the Drug Controller General of India (DCGI) to use antiviral drug Virafin for the treatment of moderate COVID-19 infections.
A single dose subcutaneous regimen of the antiviral drug will make treatment of COVID-19 disease more convenient.
In its regulatory filing, the company said, “When administered early on during COVID, Virafin will help patients recover faster and avoid much of the complications. Virafin will be available on the prescription of medical specialist for use in hospital/institutional setup.” “In the multicentric trial conducted in 20-25 centers across India, Virafin had shown lesser need for supplemental oxygen, clearly indicating that it was able to control respiratory distress and failure which has been one of the major challenges in treating COVID-19. The drug has also shown efficacy against other viral infections,” the company also said.
👉 Click here to read the latest Gujarat news on TheLiveAhmedabad.com